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Abstract
c-Myc (hereafter called Myc) belongs to a family of transcription factors that regulates cell growth, cell proliferation, and
differentiation. Myc initiates the transcription of a large cast of genes involved in cell growth by stimulating metabolism and
protein synthesis. Some of these, like those involved in glycolysis, may be part of the Warburg effect, which is defined as
increased glucose uptake and lactate production in the presence of adequate oxygen supply. In this study, we have taken a
mouse-genetics approach to challenge the role of select Myc-regulated metabolic enzymes in tumorigenesis in vivo.B y
breeding l-Myc transgenic mice, Apc
Min mice, and p53 knockout mice with mouse models carrying inactivating alleles of
Lactate dehydrogenase A (Ldha), 3-Phosphoglycerate dehydrogenase (Phgdh) and Serine hydroxymethyltransferase 1 (Shmt1),
we obtained offspring that were monitored for tumor development. Very surprisingly, we found that these genes are
dispensable for tumorigenesis in these genetic settings. However, experiments in fibroblasts and colon carcinoma cells
expressing oncogenic Ras show that these cells are sensitive to Ldha knockdown. Our genetic models reveal cell context
dependency and a remarkable ability of tumor cells to adapt to alterations in critical metabolic pathways. Thus, to achieve
clinical success, it will be of importance to correctly stratify patients and to find synthetic lethal combinations of inhibitors
targeting metabolic enzymes.
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Introduction
Activation of one of the three MYC oncogenes is frequently
selected for during tumorigenesis. These genes encode the
transcription factors c-Myc, N-Myc and L-Myc that regulate a
large number of downstream target genes. Although most of the
work on MYC oncogenes has involved their role in cell
proliferation, it is becoming clear that they may be involved in
most aspects of oncogenic transformation [1]. As such, unravelling
the mechanisms by which Myc proteins activate genes, and which
are the essential genes, is paramount as studies resolving these
mechanisms may open up new avenues of targeted intervention
against various cancers.
Some of Myc’s earliest discovered transcriptional targets were
genes encoding metabolic enzymes such as Ornithine decarboxylase
[Odc] [2,3], Lactate dehydrogenase A [Ldha] [4] and Carbamoyl-
phosphate synthase/aspartate carbamoyltransferase/dihydroorotase [Cad]
[5]. Later studies using expression profiling identified even more
of these genes, indicating that Myc is a master regulator of cellular
metabolism and cell growth [6,7]. Interestingly, inhibition of
polyamine biosynthetic enzymes Odc and Spermidine synthase
have shown efficacy in chemoprevention of several cancers in
experimental models [8–14] and in colon cancer patients [15].
Furthermore, Myc-regulated Ldha, Pyruvate kinase M2 and
Glutaminase have also emerged as promising targets based on
experimental models of human cancer [16–23], suggesting that
targeting various metabolic pathways regulated by Myc may prove
beneficial in cancer therapies of patients. To gain in vivo support
for this notion we performed genetic ablation experiments in mice
to determine the individual contribution to tumorigenesis of three
different Myc-regulated metabolic enzymes.
Results
To identify critical Myc-regulated metabolic enzymes, we
performed Illumina bead chip arrays on RNA isolated from 4–6
week old wildtype or precancerous, B cell lymphoma-prone l-Myc
transgenic mice, where the human MYC gene is under the control of
the immunoglobulin (Ig) l enhancer [24]. Interestingly, when we
performed unsupervised Hierarchical clustering on 153 genes (Table
S1) encoding metabolic enzymes involved in glycolysis, the Kreb’s
cycle, oxidative phosphorylation, serine synthesis and one-carbon
PLoS Genetics | www.plosgenetics.org 1 March 2012 | Volume 8 | Issue 3 | e1002573metabolism, all expression profiles from Myc-transgenic B cells
grouped together despite some intra-individual expression level
differences that could be due to expression levels of MYC and
developmental stage of the B-cell compartment (Figure 1A). Largely,
these data are supportive of the Myc target gene database (http://
www.myccancergene.org).
Many tumor cells use aerobic glycolysis, producing lactate even
in the presence of oxygen (the Warburg effect) [25]. Most of the
glucose from the enhanced glucose uptake is however used to
provide metabolites for anabolic processes, such as fat and
nucleotide synthesis. Glycolysis and nucleotide metabolism are
linked at several steps including the pentose phosphate shunt and
via the phosphorylated pathway of serine synthesis (Figure S1). In
the latter, 3-phosphoglycerate dehydrogenase (Phgdh) catalyzes
the first step and serine hydroxymethyltransferases (Shmt1 and
Shmt2) use the final product to produce folate metabolites that are
critical for several metabolic pathways including methylation and
thymidylate synthesis. Given that Myc regulates genes involved in
many metabolic pathways we decided to focus on genes that were
induced by Myc and for which there were genetic tools accessible
at the start of this project. qRT-PCR analysis confirmed that the
selected genes had elevated expression in Myc-transgenic B cells
(Figure 1B).
Shmt1 and Shmt2 protein levels and their combined activity are
elevated in B cells from l-Myc transgenic mice (Figure S2A and
S2B). So to analyze the role of Shmt1 in Myc-induced
tumorigenesis, we obtained embryonic stem (ES) cells carrying a
gene-trapped allele of Shmt1, which were injected into blastocysts
to generate chimeric mice. The offspring from these mice
generated wildtype, heterozygous or homozygous Shmt1 knockout
mice at the expected Mendelian frequency (Figure S2C and S2D),
corroborating a recent publication reporting that Shmt1 is
dispensable for mouse development [26].
The homozygous Shmt1 mutant mice did not express any Shmt1
protein in the tissues analyzed (Figure S2E) making them suitable
for the assessment of the role of this gene for Myc-induced
tumorigenesis. To that end, we first back-crossed the Shmt1
knockout mouse for 10 generations to the C57BL/6 strain and
then the interbred it with 3 different tumor models where Myc is
either the direct cause of transformation (l-Myc transgenic mice,
Figure 2A [24]) or constitutes an important circuit (p53 knockout
mice, Figure 2B [27] and Apc
Min mice of intestinal tumorigenesis,
Figure 2C [28]). Surprisingly, we did not observe any major
negative impact of Shmt1 loss on tumor initiation and development
in these models. The only significant effect was a clear acceleration
of disease in the l-Myc transgenic mice (Figure 2A), suggesting a B-
cell specific event. Taken together these data argue against Shmt1
as a target for chemotherapy.
Serine and folate metabolites can also be made via pathways
involving Shmt2 and Phgdh. However, to assess the role of Shmt2,
we were forced to take a different approach, as Shmt2 gene-trap
clones or knockout mice were not available when initiating this
project. We hence infected Colon 26 cells, which carry an NMU-
induced Kras mutation [29], with lentiviruses expressing shRNA
directed against Shmt2 and Phgdh. Despite achieving potent
knockdown levels, we did not observe any effect on viability or
ability to form subcutaneous tumors when injected into syngenic
Balb/c mice, as compared to cells infected with a control lentivirus
(Figure S3A and S3B).
To further assess the effect of Phgdh loss in different tumor
models, we obtained a Phgdh knockout mouse. Since Phgdh is
essential for neurogenesis [30], Phgdh null embryos die at around
embryonic day (E) 13.5, which prevented us from analyzing the
effects of loss of Phgdh by conventional breeding to our tumor
models. We therefore started out by assessing the impact of
removal of just one allele of Phgdh on tumorigenesis in l-Myc
transgenic mice and in Apc
Min mice. At variance with Odc, which is
haploinsufficient for tumor progression in these models, Phgdh
heterozygosity did not impact tumorigenesis in these tumor models
(Figure 3A and 3B), despite the 50% reduction in Phgdh activity
(Figure 3C).Asanalternativeapproach,wecrossed l-Myc;Phgdh
+/2
mice with Phgdh
+/2 mice and isolated hematopoietic stem cells from
E13.5 fetal livers. These cells were then used to reconstitute lethally
irradiated syngenic recipients, creating lymphoma-prone mice with
varying expression of Phgdh(Figure 3D). Even inthis setting,Phgdh
was dispensable for Myc-induced tumorigenesis (Figure 3E),
suggesting that hematopoiesis and Myc-driven tumorigenesis can
occur in the absence of Phgdh.
Phgdh is linked to glycolysis and could potentially divert
metabolites away from pyruvate usage in the TCA cycle in the
mitochondrion. Pyruvate is also kept from entering the TCA cycle
via the action of Ldha, encoded by another Myc-regulated gene
[23]. Except for RNAi or antisense studies in established tumors, it
is not known whether Ldha is needed for the actual transformation
event in vivo. To assess this we used a mouse model carrying a
procarbazine-induced homozygous germline mutation of Ldha
[31]. The mutation has been mapped to an aspartate 223 to
histidine exchange which results in a very strong phenotype in
erythrocytes causing anemia that is counteracted by extra-
medullary hematopoiesis with an associated splenomegaly (Figure
S4A). We crossed Ldha mutant mice with l-Myc mice to generate
mice of all relevant genotypes. Some of these mice were sacrificed
before they developed tumors to allow analysis of Ldh activity in
splenic B cells. Other mice were aged and monitored for tumor
development. As seen in Figure S4B, splenic B cells from l-Myc
mice exhibited an elevated level of Ldh activity - consistent with
the expression analysis in Figure 1 – whereas the Ldha mutation
severely diminished Ldh activity in B cells from both non-
transgenic and Myc transgenic mice (Figure S4B). Unexpectedly,
the Ldha mutation did not affect Myc-induced B-cell lymphoma-
genesis. In two independent survival curves generated at Umea ˚
University and Helmholtz Center Munich the median survival
time for l-Myc;Ldha
mut/mut was similar to that of l-Myc;Ldha
wt,
with no statistical difference (Figure 4A for the Umea ˚-generated
survival curve; Munich curve is shown in Figure S4C).
Our unexpected results suggest several possibilities: either Ldha
is dispensable for Myc-induced lymphomagenesis; or a compen-
satory mechanism is occuring; or Ldha deficiency alters the route
of transformation. Firstly, a compensation by another Ldh form is
improbable since Ldh activity and Ldhb expression were very low
or absent in tumors arising in l-Myc;Ldha
mut/mut mice (Figure S4D
and S4E). Secondly, Myc-induced lymphomagenesis in the mouse
Author Summary
Cancer occurs when cells change their behavior and start to
divide in an uncontrolled manner. To achieve this altered
behavior, cells need to change their metabolism to be able
to grow even when nutrient and oxygen supplies are
limiting. Therefore, targeting metabolic pathways could be
used to treat patients suffering from cancer. Here we
studied a gene called MYC, which can regulate many
metabolic pathways. By using genetically modified mice we
can show that tumors have a remarkable ability to change
their metabolism, even if key enzymes are removed. Taken
together, our data suggest that metabolic disturbance by
drugs in the clinic may present a future challenge.
Metabolic Pathways Can Be Redundant in Lymphomas
PLoS Genetics | www.plosgenetics.org 2 March 2012 | Volume 8 | Issue 3 | e1002573Figure 1. Myc regulates the metabolic transcriptome. (A) Unsupervised hierarchical clustering of Illumina bead arrays made from RNA of
splenic B cells from three wildtype and four precancerous l-Myc transgenic mice. See Table S1 for genes used in the clustering. (B) qRT-PCR
confirmation of 4 of the 20 most significantly, or most elevated expressed genes, in B220-sorted B cells from l-Myc transgenic mice. *indicates
p,0.05 and ** indicates p,0.01.
doi:10.1371/journal.pgen.1002573.g001
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mutations of tumor suppressors and other oncogenes to block the
oncogenic stress response of Myc [32,33]. Hence, overexpression
of anti-apoptotic proteins such as Bcl-2 or genetic deletion of one
tumor suppressor allele such as Arf or p53 dramatically accelerates
lymphomagenesis [34–36]. To neutralize the genetic heterogeneity
in the cooperating oncogenic lesion during lymphomagenesis we
interbred the p53 knockout mouse with the Ldha mutant mouse
and the l-Myc mouse. l-Myc;wildtype, l-Myc;Ldha
mut/wt or l-
Myc;Ldha
mut/mut were made heterozygous for p53 by interbreeding.
All mice developed disease at an accelerated rate as compared to
l-Myc mice (Figure 4B). The tumors that developed lost the
wildtype p53 allele (data not shown). Moreover, the frequency of
p53 mutation in the tumors that developed in the first cross
(Figure 4A) was not different between Ldha genotypes (data not
shown). We conclude that Myc-induced lymphomagenesis can
occur normally in mice lacking fully functional Ldha.
Studies using antisense or RNAi have shown that Ldha is
important for breast carcinoma, neuroblastoma, fumarase-defi-
cient renal cell cancers, as well as fibroblast and B-cell tumor cells
in vitro [17,18,20,23,37]. Although the specific combination of Myc
overexpression with loss of p53 was previously unexplored, other
explanations to the differences between our findings and those of
others, like experimental methods, culture conditions, oxygen
supply or oncogenic pathway, could be at play. To test if a
dependency of Ldha could be revealed in settings where Myc is
downstream rather than the primary oncogenic instigator, we
interbred Apc
Min mice and p53 knockout mice with the Ldha
mutant mouse. As seen in Figure 4C, Ldha deficiency did not
impact adenomagenesis in the Apc
Min mice. However, we also
created p53
2/2;Ldha
mut/mut or Ldha
wt mouse embryo fibroblasts
(MEFs) which were transduced with an oncogenic H-Ras (pBabe-
Hras
G12V-puro) retrovirus. Interestingly, whereas no growth defect
could be observed in vitro, the Ldha mutant Ras-transformed p53
knockout MEFs generated significantly smaller tumors in vivo that
appeared less vascularized (Figure 4D and Figure S5A). This effect
was not a result of varying expression of oncogenic H-Ras in the
different tumors (Figure S5B). Moreover, Colon 26 cells with an
endogenous oncogenic Kras allele could not be propagated when
transduced with lentiviruses expressing two different Ldha shRNAs
despite the fact that these constructs were not lethal in NIH 3T3
cells (data not shown). To confirm the dependency on Ldha we
also co-transfected a GFP expressing plasmid with the lentiviral
expression constructs expressing Ldha shRNA into Colon 26. As
seen in Figure S3C and S3D, we were able to knockdown
expression of Ldha in the cells, which resulted in a progressive loss
of cells from 48 h post-transfection.
To investigate the ability of Ldha-deficient fibroblasts to
proliferate in a hypoxic environment, NIH 3T3 cells infected
with Myc (pWLBlast-c-Myc) or Ras (pBabe-Hras
G12V-hygro)
retroviruses and control or Ldha shRNA lentiviruses were exposed
to hypoxia. As expected, hypoxia resulted in the induction of Ldha
and Pdk1, both downstream targets of Hif1a (Figure S5C).
Interestingly, cells infected with the Ldha shRNA incorporated less
3H-thymidine than cells infected with a control lentivirus (Figure
S5D). Thus, Ldha is required under defined conditions such as
hypoxia and/or in cells with a deregulated Ras pathway.
Therefore an Ldha dependency may not be manifested in a
Myc-induced lymphomagenesis setting.
In agreement with this notion, the l820 mouse B-cell
lymphoma line established from l-Myc mice [38] succumbed to
apoptosis when exposed to hypoxia (Figure S6A and S6B),
regardless of whether or not Ldha was knocked down (Figure S6C).
In addition, Ldha knockdown did not impact lymphomagenesis in
vivo (Figure S6D), although knockdown still left a substantial
amount of Ldha transcript and activity in this highly Ldha-
expressing cell line (Figure S6C and S6E). Nevertheless, given the
Figure 2. Shmt1 loss accelerates lymphomagenesis in l-Myc
transgenic mice. (A) Survival curve of l-Myc mice generated from
interbreedings between Shmt1 knockout and l-Myc transgenic mice. l-Myc;
Shmt1
+/+n=19, l-Myc;Shmt1
+/2n=18, l-Myc;Shmt1
2/2n=20. (B) Survival
curve of p53 knockout mice of the indicated Shmt1 genotypes. p53
2/2;
Shmt1
+/+ n=22, p53
2/2; Shmt1
2/2 n=21. (C) Amount of adenomas in
Apc
Min mice with different Shmt1 genotypes.
doi:10.1371/journal.pgen.1002573.g002
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S6B), it is unlikely that tumorigenesis in this model contains a
hypoxic component and thereby dependency on elevated Ldha
activity. Indeed, immunohistochemistry showed that Ldha wildtype or
mutant lymphomas from l-Myc mice exhibited a remarkable sparse
expression of angiogenic markers CD34 and SMA (Figure S7A).
Figure 3. Phgdh is dispensable for lymphomagenesis in l-Myc transgenic mice. (A) Survival curve of l-Myc mice generated from
interbreedings between Phgdh
+/2 and l-Myc transgenic mice. l-Myc; Phgdh
+/+ n=21, l-Myc; Phgdh
+/2 n=23. (B) Amount of adenomas in Apc
Min mice
with different Phgdh genotypes.(C) Enzymatic activity of Phgdh analyzed in sixl-Myc; Phgdh
+/+ andin six l-Myc; Phgdh
+/2 lymphomas. (D) Western blot
analysis confirming that Phgdh is absent in tumors arising in recipient mice from l-Myc;Phgdh
2/2 embryos. (E) Survival curve of C57BL/6 mice
transplanted with l-Myc transgenic E13.5 FLC of indicated Phgdh genotype. l-Myc; Phgdh
+/+ n=5,l-Myc; Phgdh
+/2 n=14, l-Myc; Phgdh
2/2 n=7.
doi:10.1371/journal.pgen.1002573.g003
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that nutrients and oxygen can diffuse in these non-solid tumors. The
staining results were not due to non-functional antibodies as they
readily detected the angiogenic markers in normal spleen and in
lymphomas that had disseminated in spleens of l-Myc mice (Figure
S7B). It therefore appears as if lymphomas arising in lymph nodes of
l-Myc mice are neither angiogenic, hypoxic or dependent on Ldha
activity.
Discussion
We are today beginning to appreciate the fact that oncogenes
and tumor suppressor genes not only regulate cell proliferation,
immortalization, apoptosis, metastasis and angiogenesis [39] but
also cellular metabolism. The change in metabolism and the
Warburg effect were for a long time believed to be self-evident and
secondary to transformation. It is now known that the metabolic
changes occur simultaneously and are governed by the same signal
transduction pathways as those governing cell proliferation [40].
Since different tumor cells transform in response to variations of
oncogenic mutations it is therefore likely that tumor cells can, or
even have to, make different metabolic adaptations as well. Some
of these adaptations may make the cells dependent on a certain
enzyme, whereas others do not. Our study highlights the Ras
oncogene as a potential pathway that requires Ldha, illustrated in
Ras-transformed fibroblasts and Colon 26 cells, which carry an
endogenous Kras mutation. Indeed, it has previously been shown
that neu-transformed breast cancer cells are sensitive to Ldha
inhibition by RNAi [37]. Since these cells have an activated Ras
pathway [41], this may explain why knockdown of Ldha sensitizes
these cells. The potential explanation why Ras-induced fibrosar-
comas are sensitive to the Ldha mutation in vivo is that they are
not inherently angiogenic, making them sensitive to metabolic
perturbation before angiogenesis has occurred. The fact that Myc
can stimulate angiogenesis independently of hypoxia-inducible
factors [42–44] may account for the lack of impact on lym-
phomagenesis upon mutation of e.g. Ldha. Indeed, we show here
that lymphomas from l-Myc mice are very sensitive to hypoxia,
Figure4.Ldhais dispensableforMyc-inducedlymphomagenesisbutnotforthedevelopmentofRas-inducedfibrosarcomas.(A)Survival
curve of l-Myc mice generated from interbreedings between Ldha
mut/mut and l-Myc transgenic mice. l-Myc;Ldha
+/+ n=13, l-Myc;Ldha
+/mut n=26, l-
Myc;Ldha
mut/mut n=21. The p-value is derived from comparing the survival of l-Myc;Ldha
+/+ to l-Myc;Ldha
mut/mut mice. (B) Survival curve of l-Myc mice
generatedfrom interbreedings between Ldha
mut/mut, p53 knockoutandl-Myc transgenic mice.l-Myc;p53
+/2;Ldha
+/+ n=19,l-Myc;p53
+/2;Ldha
+/mut n=9,
l-Myc;p53
+/2;Ldha
mut/mut n=17.Thep-value isderivedfrom comparingthe survivalofl-Myc;p53
+/2;Ldha
+/+ tol-Myc; p53
+/;Ldha
mut/mut mice.(C) Amount
of adenomas in Apc
Min mice with different Ldha genotypes. (D) MEFs of different Ldha genotypes were infected with oncogenic Ras. After subcutaneous
injection into syngenic C57BL/6 mice, tumor weights were monitored 16 days post-injection. Two mice were injected with cells per Ldha genotype and
the experiment was repeated with three different MEF isolates per Ldha genotype.
doi:10.1371/journal.pgen.1002573.g004
Metabolic Pathways Can Be Redundant in Lymphomas
PLoS Genetics | www.plosgenetics.org 6 March 2012 | Volume 8 | Issue 3 | e1002573most likely since they are Myc-driven and therefore rely on the
TCA cycle and oxidative phosphorylation [45].
Folate biosynthesis has been linked to cancer both from studies
on dietary supplements and by the identification of polymorphisms
in genes encoding enzymes in folate biosynthesis like SHMT1,
MTHFR and TS [46]. In addition, certain drugs like methotrexate
target the folate biosynthetic pathway suggesting that this pathway
is of critical importance for tumor cell survival. Interestingly, Shmt2
was first identified as a target in a screen for genes that can rescue
the growth defect of Myc null rat fibroblasts [47]. In the same study
Shmt1 was also shown to be a Myc transcriptional target gene but it
was not further functionally characterized. Herein, we provide
evidence that Shmt1 is dispensable for Myc-induced lymphoma-
genesis and that its deletion even accelerates tumorigenesis. The
reason for this acceleration is unknown. It could involve effects on
senescence or B-cell development as deletion of genes like Suv39h1
and E2f2 accelerates tumorigenesis by these mechanisms,
respectively [48,49]. However, our data corroborate other very
recent studies. Using an Shmt1 knockout mouse [50], the Stover
group showed that deletion of one allele of Shmt1 promotes
adenomagenesis in the Apc
Min mice when administered a special
diet [26]. In our study the Shmt1 heterozygous Apc
Min mice also
have the largest mean amount of adenomas, albeit we did not
investigate the impact of diet on this model. Interestingly,
homozygous deletion of Shmt1 did not impact adenoma formation
in Apc
Min mice since there was a compensatory increase in
thymidylate kinase (TK1) expression [47]: a salvage pathway for
thymidine synthesis. We observed a stronger effect on acceleration
of Myc-induced lymphomagenesis in homozygous mutant Shmt1
mice, suggesting that the salvage pathway is not completely
penetrant. Taken together, we would argue that Shmt1 is a tumor-
suppressing modifier in the context of B-cell lymphomas and
colorectal adenomas.
One of the most important reasons for the systematic analysis of
Myc target genes in tumorigenesis is the potential of identifying or
validating future drug targets. Our lymphoma and adenoma data
cast doubt on the utility of developing targeted interventions
against Ldha, Phgdh and Shmt1. On the other hand, in these
models, tumors arise in mice carrying germline mutations of both
the oncogenic lesion and the genes encoding the metabolic
enzymes. It is thus plausible that adaptations have occurred during
development that would not have occurred in cells acutely exposed
to an inhibitor. Nevertheless, our data suggest that tumor cells
eventually will develop resistance to putative treatments directed
against metabolic enzymes since tumor growth undoubtedly can
occur in the absence of Shmt1, Phgdh or Ldha. Therefore, a
correct stratification is needed to identify patients whose tumors
would be sensitive to inhibitors that are under development, for
instance against Ldh [6,18]. Such stratification can be performed
based on which oncogenic driver mutation the tumor has
acquired. As shown here, oncogenic Ras or pathways utilizing
this circuit could be a potential parameter. Moreover, two
independent studies published while revising this manuscript
suggest that PHGDH amplification could be another oncogenic
driver mutation in breast cancer and melanoma, which would
sensitize cells to inhibition of Phgdh [51,52]. As shown here and in
these two studies, Phgdh is important in some but not all contexts.
To date, very few inhibitors against Ldh have been identified
and those known are either poorly bioavailable and/or have other
targets. For instance, sodium oxamate is used in high millimolar
concentrations but inhibits aspartate aminotransferase at concen-
trations where lactate production is not even affected when tumor
cell growth is [53]. Gossypol, a natural compound from cottonseed
first identified as a male contraceptive, also inhibits anti-apoptotic
proteins of the Bcl-2 family making interpretation of anti-cancer
activity difficult [54]. Even if improved inhibitors are developed
the issue whether or not Ldh is a good target is unresolved. Our
genetic study shows that cells carrying a defective Ldha are
capable of forming tumors, albeit hindered by hypoxia. We and
others also show that ablation of Ldha by RNAi can be detrimental
for the cell. It is thus possible that either cell context determines
sensitivity, or that the ablation of Ldha protein (RNAi) is more
severe than inhibition of its activity (D223H mutation). This
notion would lend support to the idea that Ldha may have other
functions, potentially disconnected from its activity [55]. For
instance, Ldha can be phosphorylated (Tyr238) and localized to
the nucleus [56] and has recently been shown to exist in
transcription complexes in ES cells [57]. Future studies should
address if glycolysis-independent functions of Ldha, as suggested in
transcription [58,59], are the most important functions in some
tumors. If so, focus on the development of new therapies should
aim at blocking all activities of Ldha.
Materials and Methods
Ethics statement
All animal experiments were performed in accordance with the
Regional Animal Ethic Committee Approval no. A6-08 or
no. A18-08.
Mouse colonies
All transgenic mice in the study were on pure C57BL/6
background. The l-Myc-mice and the Ldh
mut/mut mice have been
previously described [24,31]. The p53 knockout mice and the
Apc
Min mice were from Jackson Labs, the C57BL/6 and Balb/c
mice used as recipients were from Taconics, and the Phgdh
knockout mice were from RIKEN BRC, Japan. Shmt1 knockout
mice were generated by blastocyst injection of gene-trapped ES
cells (clone AD0236, Sanger Institute Gene-trap Resources) at
Umea ˚ Transgene Core Facility. After confirmation of germline
transmission, mice were backcrossed to C57BL/6 for at least ten
generations. Illumina SNP genotyping confirmed that the mice
were at least 96% C57BL/6 before starting interbreeding with l-
Myc transgenic mice, p53 knockout mice and Apc
Min mice.
Tumor monitoring and analyses
All mice used in the study were monitored by group members
and personnel at the animal facilities (Umea ˚ Transgene Core
Facility or Helmholtz Centre, Munich). When showing signs of
disease, l-Myc mice were sacrificed and lymphomas were collected
for analyses. Dates of sacrifice were entered into GraphPad Prizm
software for the generation of survival curves. Lymphomas were
either snap frozen for RNA and protein analyses, or formalin-fixed
and embedded in paraffin. Paraffin blocks were sectioned and
processed by standard immunohistochemistry methodology using
antibodies directed against smooth musle actin (SMA; Sigma)
or CD34 (Abcam) at the Histocenter core facility (Go ¨teborg,
Sweden).
The Apc
Min mice used for adenoma formation studies were
sacrificed and analyzed between 120–140 days of age, or when
showing signs of disease. The small intestine and colon were
dissected out, washed with phosphate-buffered saline and cut
length-wise at which point adenomas were counted and tissues
were harvested for analyses. Adenomas were counted using
dissection microscope as well as by eye by two independent
observers. The adenomas were scored irrespective of size and
numbers per mouse were entered into GraphPad Prizm software
for generation of graphs.
Metabolic Pathways Can Be Redundant in Lymphomas
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The analysis of gene expression changes between magnetically
sorted B cells from wildtype or l-Myc transgenic mice was
performed using the Illumina BeadChip system. For in vitro
transcription amplification, 200 ng of RNA was used with the
Illumina RNA Amplification Kit (Ambion). Amplified RNA
(1.5 mg) was hybridized to the Sentrix MouseRef-8 Expression
Beadchip (Illumina). The primary data were collected from the
BeadChips using the manufacturer’s BeadArray Reader and
analyzed using the supplied scanner software. Data normalization
was performed by cubic spline normalization using Illumina’s
Beadstudio v3 software. Clustering and visualization of genes
encoding metabolic enzymes was done using the Spotfire software.
Cell culture
MEFs were generated by mechanical disruption and trypsin-
digestion of E13.5 embryos from which the fetal liver and the head
had been removed. The single-cell suspension was grown in
DMEM supplemented with 10% fetal bovine serum (FBS), 50 mM
b-mercaptoethanol, 16 glutamine, pyruvate, non-essential amino
acids and antibiotics (Invitrogen). 293T cells and NIH 3T3 (from
ATCC) were routinely maintained in DMEM supplemented with
10% FBS, glutamine and antibiotics. Colon 26 cells (from Cell Line
Services) were cultured in RPMI supplemented with 10% FBS,
glutamine and antibiotics. The l820 cell line was established from
l-Myc transgenic mice and cultured as previously described [38].
Viral production and transductions
Retroviruses and lentiviruses were produced by calcium
phosphate-mediated transfection of 293T cells. For retroviruses
the following plasmids from Addgene were used: pBABE-
HrasG12V-puro, pBABE-HrasG12V-hygro, MSCV-Myc-IRES-
GFP, pWZL-Myc-blasticidine, pBABE-puro, pBABE-hygro to-
gether with pCL-Eco (encoding gag, pol and ecotropic envelope).
Lentiviruses for RNAi were made using pLKO.1 puro vectors
expressing shRNAs (Sigma Mission RNAi), together with
packaging plasmids pCMV R8.2dvpr and pHCMV-EcoEnv (both
from Addgene). Two or three different shRNAs were used per
gene (Table S2) and they were compared to a control pLKO
vector expressing a control shRNA with no known target in the
mouse genome (non-target vector from Sigma). Thirty-six hours
post-transfection, the media was harvested four times during an
additional 36 h. The virus was filtered and either frozen down in
aliquots or applied on target cells in the presence of 4–8 mg/ml
polybrene. Following antibiotics selection for 48 h (or GFP
analysis of FACS to confirm at least 90% positive cells) cells were
expanded and used for experiments. The shRNA-containing
viruses were always introduced into NIH 3T3 cells after the
transduction with control, Myc or Ras retroviruses.
Subcutaneous tumor formation and analyses
MEFs used for sarcoma formation studies were infected with
retroviruses encoding oncogenic Hras, whereas Colon 26 cells
were infected with lentiviruses expressing shRNA against Shmt2,
Phgdh and Ldha. For MEFs, 1610
6 were injected subcutaneously
into C57BL/6 recipients, whereas 5610
5 Colon 26 cells were
mixed with Matrigel (1:1) and injected into Balb/c mice. When
tumors appeared, the mice were sacrificed and tumors were
weighed and material was harvested for analyses. For immuno-
fluorescence, formalin-fixed tumors were embedded in paraffin
and sectioned (8 mm) onto glass slides. Following deparaffinization
and rehydration, slides were either stained with H&E or subjected
to Hoechst and antibody staining using Cy3-conjugated control or
anti-smooth muscle actin antibody (Sigma) according to standard
methodology. Following mounting the sections they were analyzed
in a fluorescence microscope.
Fetal liver transplants
Fetal livers of E13.5 embryos were dissected out of embryos
from timed pregnancies between l-Myc; Phgdh
+/2 males and
Phgdh
+/2 females. Each individual liver was dissociated through a
cell strainer and injected via the tail-vein into one lethally gamma-
irradiated (9.25 Gy) C57BL/6 recipient. Tissue from each embryo
was taken for genotyping and the mice positive for the l-Myc
transgene were followed for lymphoma development and treated
as previously described in Mouse colonies and Tumor monitoring and
analyses.
Protein and RNA expression
For protein expression analyses by Western blot, cells and
tumors were lysed in an appropriate amount of lysis buffer on ice
for 30 min. Following sonication, clearing by centrifugation and
protein determination, an equal amount of protein per well was
loaded on SDS-PAGE gels and separated by electrophoresis. The
proteins were transferred to a nitrocellulose membrane, which was
subsequently blocked with TBST containing 5% non-fat dried
milk. The membranes were then blotted with primary and
horseradish peroxidise-conjugated secondary antibodies dissolved
in blocking solution. After washing with TBST, the bound proteins
were visualized by enhanced chemoluminescence. The primary
antibodies used were from BD Biosciences (H-Ras), Cell signalling
(c-Myc and Pdk1), Sigma-Aldrich (Ldha, Ldhb, Shmt1, Shmt2
and b-actin) and Atlas Antibodies (Shmt1 and Phgdh).
RNA expression was measured by quantitative reverse tran-
scriptase PCR (qRT-PCR). Briefly, RNA was prepared using the
NucleoSpin RNA II kit (Macherey-Nagel). cDNA was prepared
using the First strand synthesis kit (Fermentas) and the PCR was
run using the KAPA mastermix (Biotools) on an iQ real-time PCR
machine (Bio-Rad). Primer sequences can be found in Table S3.
Hypoxia experiment
NIH 3T3 cells expressing either HrasV12, c-Myc or both were
used for parallel infections of lentiviruses encoding shRNAs against
Ldha. The same amount of cells were seeded in 24-well format and
subsequently infected. 72 hours post infection, each well was split
into 3696 well format in duplicate plates. One set of plates was
placed in a hypoxic environment (using the Modular incubator
chamber, Billups-Rothenberg Inc.) for 40 hours after which the
hypoxic treatment was terminated and 3H-thymidine was added to
allwells. Aftertwo hours, theplateswerefreeze-thawed and the cells
harvestedonto glassfibre filters.Microscint scintillationsolutionwas
administered to the dried filter, which were subsequently counted
on a TopCount scintillation counter. l820 cells were subjected to
hypoxia in 24 well plates or 25 cm
2 flasks (2610
5 cells/ml) and were
harvested for cell counting and apoptosis analyses or RNA analyses,
respectively. For apoptosis analyses, cells were stained with
Vindelo ¨vs reagent (10 mM Tris, 10 mM NaCl, 75 mM propidium
iodine, 0.1% Igepal, and 700 units/liter RNase adjusted to pH 8.0)
and then analyzed with a FACScalibur flow cytometer (BD
Biosciences). Apoptosis was determined using DNA histograms
and was based on the number of cells that carried less than diploid
DNA content (sub-G1) in a logarithmic FL2 channel.
Enzyme activity assay
Total protein lysates were prepared as described above and the
same amount of protein was assayed for LDH activity using the
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were read using the Tecan Infinite200 plate reader at 492 nm.
Lysates were also used to assess Shmt activity and Phgdh in
accordance with published methods [60,61].
Supporting Information
Figure S1 Metabolic pathways linking glycolysis and serine/
folate metabolism. The enzymes: LDH (lactate dehydrogenase);
PHGDH (3-phosphoglyerate dehydrogenase); PSAT (phosphoser-
ine aminotransferase); PSPH (phosphoserine phosphotase); SHMT
(serine hydroxymethyltransferase 1 and 2); DHFR (Dihydrofolate
reductase); TYMS (Thymidylate synthase).
(PDF)
Figure S2 Further characterization of Shmt1 mutant mice. (A)
Protein expression of Shmt1, Shmt2 and Phgdh in l-Myc cells and
tumors. (B) Shmt activity in B cells from three 4-weeks old l-Myc
and three wildtype littermates. (C) Genomic organisation of the
mouse Shmt1 locus indicating insertion of the gene-trap cassette.
(D) Typical PCR genotyping results of tail DNA from offspring of
matings between heterozygous Shmt1 mutant mice. (E) Western
blot analysis showing absence of detectable protein in tissues from
Shmt1 mutant mice.
(PDF)
Figure S3 Ldha is essential for Colon 26 cells. (A) Subcutaneous
tumors arising in syngenic Balb/c mice by injecting Colon 26 cells
infected with lentiviruses expressing shRNAs against Shmt2 and
Phgdh (three separate hairpins of each). The symbols correspond to
the different hairpins used in the experiment. In the control group,
black symbol represents uninfected (UI) cells and white refers to
the control non-targeting shRNA (NT). In the Phgdh shRNA
group, white symbol represents shRNA#2, grey symbol
shRNA#3 and black symbol shRNA#5. In the Shmt2 group,
white symbol represents shRNA#3, grey symbol shRNA#4 and
black symbol shRNA#5. See Table S2 for details on the specific
shRNA constructs. * Colon 26 cells expressing Ldha shRNA#2
and shRNA#5 were depleted in culture and could not be
transplanted (B) The level of knockdown in the tumors from panel
C was analyzed by qRT-PCR. (C) Colon 26 cells were transiently
co-transfected in 6-well plates with a GFP-expressing plasmid and
a plasmid expressing either a non-targeting (NT) shRNA or Ldha
shRNA#5. Cells were analyzed for GFP and found to be 50–60%
GFP-positive 24 h post-transfection (data not shown). At 72 h
post-transfection, cells were counted. Shown is the mean 6 SD of
three independent experiments. *p,0.05 (D) The same cells as in
C were analyzed by qRT-PCR to confirm Ldha knockdown.
(PDF)
Figure S4 Further characterization of Ldha mutant mice. (A)
Splenomegaly in Ldha mutant mice. (B) Ldh activity in
magnetically sorted splenic B cells derived from mice of indicated
genotypes. (C) Survival curve of l-Myc mice generated from
interbreedings between Ldha
mut/mut and l-Myc transgenic mice
generated at Helmholtz Center in Munich. (D) Ldh activity in
some of the tumors developed in mice described in Figure 4A. (E)
Western blot analysis of Ldha and Ldhb in some of the tumors
developed in mice described in Figure 4A and 4B.
(PDF)
Figure S5 Hypoxia sensitizes fibroblasts cells to Ldha inhibition.
(A) Immunofluorescence analysis of a-Smooth muscle actin in
representative sarcomas from Figure 4D. Hoechst staining was
used to stain the nuclei. (B) Western blot analysis for Ha-Ras on
representative sarcomas from Figure 4D. (C) NIH 3T3 cells were
infected with Myc, Ras or Myc+Ras retroviruses, followed by
lentiviral infection with a control or an Ldha-targeting shRNA.
The cells were subjected to hypoxia and cells were either analyzed
by Western blot using antibodies against Ldha or Pdk1 (Hif target)
(E) or incubated with radiolabelled thymidine to measure cell
proliferation.
(PDF)
Figure S6 Myc-induced lymphoma cells are sensitive to
hypoxia. (A–B) l820 cells infected with lentiviruses expressing a
non-target control shRNA (NT) or shRNAs against Ldha were
subjected to hypoxic conditions. Quantification of apoptosis was
performed by measuring the sub-G1 content using the gate shown
in A and cell numbers were collected by counting viable cells. (C)
qRT-PCR analysis for Ldha and Pdk1 in the cells analyzed in B. (D)
l820 cells carrying an shRNA against Ldha or a control shRNA
were transplanted into syngenic C57BL/6 recipients via the tail
vein and monitored for tumor growth. (E) Ldh activities of l820
cells infected with indicated lentiviruses.
(PDF)
Figure S7 Nodal lymphomas from l-Myc transgenic mice
express less angiogenic markers than splenic lymphomas. A)
Paraffin-embedded lymphomas developed in lymph nodes of l-
Myc or l-Myc;Ldha
mut/mut mice were sectioned and stained with
antibodies directed against angiogenic markers CD34 (brown
staining) and SMA (red staining). Shown is one representative field
of view encompassing most of the lymphoma (406) or a larger
magnification of the dashed square (2006). B) Paraffin-embedded
spleens from wildtype mice or lymphomas developed in spleens of
l-Myc or l-Myc;Ldha
mut/mut mice were sectioned and stained with
antibodies directed against angiogenic markers CD34 (brown
staining) and SMA (red staining). Shown is one representative field
of view at 2006.
(PDF)
Table S1 Expression of genes used in the unsupervised
hierarchical clustering shown in Figure 1. Gene list is sorted
based on the average fold-change between RNA expression in
wildtype (wt) and l-Myc splenic B cells.
(XLSX)
Table S2 List of shRNAs used in the study. The shRNAs came
from the TRC1.0 mouse lentiviral library and their library
number is indicated.
(XLSX)
Table S3 Sequences of qRT-PCR primers used in the study.
Primers were designed using the SciTools at www.idtdna.com.
(XLSX)
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